Wound Management buys ortho firm to exploit $10bn opportunity
This article was originally published in Clinica
In a bid to broaden its platform technologies that target growing patient populations, Wound Management Technologies has purchased biomaterial expert Resorbable Orthopedics. The deal provides Wound Management with complementary orthopaedic biomaterials such as a resorbable bone wax used to stop blood flow and a delivery system for osteogenic and osteoinductive bone void fillers. According to Fort Worth, Texas-based Wound Management, the orthopaedic biomaterial market is worth around $10bn and is driven by improved patient benefits, shorter FDA approval cycles and an ageing population. The total market value for the biomaterial sector is approximately $28bn and is expected to exceed $58bn in the next five years. For an undisclosed fee, Resorbable Orthopaedics has become a wholly-owned subsidiary of Wound Management.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals